|本期目录/Table of Contents|

[1]杨月,张振宇.二丁酰环磷腺苷钙联合维生素C治疗重度寻常型银屑病疗效分析及安全性评价[J].医学研究与战创伤救治(原医学研究生学报),2021,23(6):604-609.[doi:10.3969/j.issn.1672-271X.2021.06.010]
　YANG Yue,ZHANG Zhen-yu.Study of the therapeutic effect and safety of the combination of calcium dibutyryladenosine cyclophosphate and vitamin C in treating psoriasis vulgaris[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(6):604-609.[doi:10.3969/j.issn.1672-271X.2021.06.010]
点击复制

二丁酰环磷腺苷钙联合维生素C治疗重度寻常型银屑病疗效分析及安全性评价()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第23卷
期数:
2021年6期
页码:
604-609
栏目:
临床研究
出版日期:
2021-12-15

文章信息/Info

Title:
Study of the therapeutic effect and safety of the combination of calcium dibutyryladenosine cyclophosphate and vitamin C in treating psoriasis vulgaris
作者:
杨月; 张振宇
作者单位：116021大连,大连市皮肤病医院药剂科（杨月、张振宇）
Author(s):
YANG Yue;  ZHANG Zhen-yu
(Department of Pharmacy, Dalian Dermatosis Hospital, Dalian 116021, Liaoning, China)
关键词:
二丁酰环磷腺苷钙; 维生素C; 寻常型银屑病; 疗效分析; 不良反应
Keywords:
calcium dibutyryladenosine cyclophosphate;  vitamin C;  psoriasis vulgaris;  therapeutic effect analysis;  adverse effect
分类号:
R758.63
DOI:
10.3969/j.issn.1672-271X.2021.06.010
文献标志码:
A
摘要:
目的探讨二丁酰环磷腺苷钙联合维生素C治疗寻常型银屑病的临床疗效及安全性。方法选择2018年10月至2019年4月在大连市皮肤病医院银屑病专科病房住院的90例重度寻常型银屑病患者，采用随机数字表法分为3组：联合组、二丁钙组、维C组，每组30例。联合组给予注射用二丁酰环磷腺苷钙40 mg联合维生素C注射液3.0 g静脉滴注；二丁钙组给予注射用二丁酰环磷腺苷钙40 mg静脉滴注；维C组给予维生素C注射液3.0 g静脉滴注；3组均以5%葡萄糖注射液250 mL为溶媒每日1次，同时给予复方维生素E乳膏、中药药浴及窄谱中波紫外线NB-UVB治疗，15日一个疗程，疗程间隔1周，共两个疗程。根据患者皮损部位与面积、红斑程度、浸润程度、鳞屑程度、自身感知等计算受累体表面积（BSA）、银屑病皮损面积和严重指数（PASI）、皮肤病生活质量指数（DLQI）、医师及患者整体评价法（PGA、VAS）的改善情况，填写药品不良反应报告表并分析药物不良反应情况。结果90例患者中，完成试验治疗及随访84例，其中联合组27例，二丁钙组 27例，维C组 30例。3组年龄、性别、体重指数、病程、既往药物过敏史及治疗前PASI、BSA评分值比较差异无统计学意义（P>0.05）。治疗结束后，联合组、二丁钙组及维C组显效率（63.0%、40.7%、23.3%）、PASI75比例（74.1%、55.6%、36.7%）、PASI90比例（51.9%、25.9%、11.1%）比较差异均有统计学意义（P<0.05），不良反应发生率（11.11%、7.41%、0%）比较差异无统计学意义（P>0.05）。而次要疗效指标采用单因素方差分析，维C组与联合组、二丁钙组在VAS、DLQI比较差异有统计学意义（P<0.05）；联合组与二丁钙组、维C组在PGA比较差异有统计学意义（P<0.05）。结论二丁酰环磷腺苷钙联合维生素C治疗寻常型银屑病比单用维生素C、二丁酰环磷腺苷钙更有效。
Abstract:
ObjectiveTo discuss the clinical therapeutic effect and safety of the combination of calcium dibutyryladenosine cyclophosphate and vitamin C in treating psoriasis vulgaris.MethodsTotally 90 patients of psoriasis vulgaris were equally divided into three groups, i.e. the combination group, calcium dibutyryladenosine cyclophosphate group and vitamin C group. The patients in combination group was given 40 mg calcium dibutyryladenosine cyclophosphate for injection and 3.0 g vitamin C injection by intravenous drip. The patients in calcium dibutyryladenosine cyclophosphate group was given 40 mg calcium dibutyryladenosine cyclophosphate for injection by intravenous drip. The patients in vitamin C group was given 3.0 g vitamin C injection by intravenous drip. The administration for the three groups was given once a day after dissolved in 250 mL of 5% dextrose injection, together with compound vitamin E cream and Chinese medicine bath. Each of the two courses lasted 15 days and was undertaken every other week. The improvement of the affected body surface area (BSA), psoriasis area and severity index (PASI), dermatosis living quality index (DLQI), and physician & patient global appraisal (PGA/VAS) was evaluated based on the skin injury part, size, erythema condition, infiltration degree, scale degree and perception of the patients, and the adverse effect report was filled.ResultsAmong the 90 patients, 84 cases finished the experimental treatment and accepted the follow-up visit, specifically 27 in the combination group, 27 in the calcium dibutyryladenosine cyclophosphate group and 30 in the vitamin C group. Before treatment, the gender, age, body mass index, course of disease, previous history of drug allergy and scores of PASI and BSA of the three groups had no statistical difference. After treatment, the difference among the marketed effective rates (63.0%, 40.7% and 23.3%) of the combination group, calcium dibutyryladenosine cyclophosphate group and vitamin C group, and the difference among their PASI75 rates (74.1%, 55.6%, 36.7%) had statistical significance (P<0.05), but the differences among the occurrence rates of adverse effect (11.11%, 7.41%, 0%) had no statistical significance (P>0.05). The differences of VAS and DLQI between the vitamin C group and the combination group, the calcium dibutyryladenosine cyclophosphate group had statistical significance, and the difference of PGA between the combination group, calcium dibutyryladenosine cyclophosphate group and vitamin C group had statistical significance.ConclusionThe combination of calcium dibutyryladenosine cyclophosphate and vitamin C is more effective than the single administration of vitamin C or calcium dibutyryladenosine cyclophosphate in treating psoriasis vulgaris.

参考文献/References:

[1]Bartlett CL，Baird TL，Helmick CG，et al. Prevalence of Psoriasis Among Adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys[J]. Am J Prev Med，2014，47(1): 37-45.
[2]王晓晖. 西南4省市银屑病流行病学调查研究[J]. 哈尔滨医药，2017，37(5): 426-427.
[3]中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南(2018简版)[J]. 中华皮肤科杂志，2019，52(4): 223-230.
[4]徐劲，乔丽，刘玮. 复方甘草酸苷联合二丁酰环磷腺苷钙治疗寻常型银屑病的疗效及安全性评价[J]. 中国药业，2016，25(16): 51-53.
[5]石健，石青岩. 氨茶碱维生素C联合治疗银屑病150例临床分析[J]. 临沂医专学报，1996，18(4): 350-351.
[6]Finlay AY. Current severe psoriasis and the rule of tens[J]. Br J Dermatol, 2005, 152(5): 861-867.
[7]Gooderham M, Papp K. Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast[J]. Bio Drugs，2015，29(5): 327-339.
[8]Keating GM. Apremilast: A Review in Psoriasis and Psoriatic Arthritis[J]. Drugs，2017,77(4): 459-472.
[9]钟文波，龚瑜，史玉玲. 银屑病伴发疾病的研究进展[J]. 国际皮肤性病学杂志，2016，42(3): 160-163.
[10]沈晓峰，尚佩生，詹明峰，等. 二丁酰环磷腺苷钙综合治疗自身敏感性湿疹临床观察[J]. 中国皮肤性病学杂志，2012，26(12): 1155-1156.
[11]赵汗庆，邵兴兰. 二丁酰环磷腺苷钙佐治轮状病毒肠炎致心肌损害疗效观察[J]. 中国中西医结合儿科学，2016，8(5): 530-532.
[12]康秀琴，崔军民. 二丁酰环磷腺苷钙联合丹参酮治疗慢性心力衰竭疗效研究[J]. 医学与社会，2015，28(B5): 244.
[13]郭虹茹，廖香兰，鄢爱红. 果糖二磷酸钠与二丁酰环磷腺苷钙治疗新生儿窒息后心肌损伤成本-效果分析[J]. 中国药业，2017,26 (20): 81-83.
[14]刘会君，卫世强，张瑞霞. 二丁酰环磷腺苷钙辅助治疗顽固性心衰的疗效探讨[J]. 国际医药卫生导报，2016，22(5): 676-678.
[15]李文秀，李永东. 二丁酰环磷腺苷钙在冠心病中的应用[J]. 医学综述，2017，23(5): 985-988.
[16]潘庆丽，高娟，王立旗.二丁酰环磷腺苷钙联合急性ST段抬高型心肌梗死的临床研究[J]. 现代药物与临床，2018，33(7): 1579-1582.
[17]王一楠. 环磷腺苷用于冠心病心绞痛治疗中的有效性、安全性[J]. 泰山医学院学报，2019，40(12): 953-954.
[18]许登明. 二丁酰环磷腺苷钙联合依达拉奉治疗急性脑出血的疗效[J]. 临床医药文献杂志，2017，26(4): 5112-5113.
[19]孙泽刚，冯泽瑞，许迎春，等. 心肌缺血再灌注致急性肺损伤的机制与二丁酰环磷腺苷钙的保护效应[J]. 中国循证心血管医学杂志，2016，8(7): 846-849.
[20]夏杨，李强，张惠军. 丹参多酚酸盐注射液联合二丁酰环磷腺苷钙治疗不稳定性心绞痛的临床疗效[J]. 中华老年心脑血管病杂志，2019，21(3): 254-257.
[21]董龙禹，李江伟，吴明毅，等. 二丁酰环磷腺苷钙预防甲状腺瘤切除术颈丛神经阻滞麻醉时血压升高的效果[J]. 武警医学，2012，23(4): 329-331.
[22]马锡俊. 窄谱紫外线联合维生素C治疗寻常型银屑病疗效观察[J]. 中国误诊学杂志，2009，9(18): 4357-4358.
[23]赵辩. 临床皮肤病学[M]. 3版. 南京: 江苏科学技术出版社，2001: 761.
[24]靳培英. 皮肤病药物治疗学[M]. 2版. 北京: 人民卫生出版社，2009: 545-546.
[25]鲁智勇，郑捷. 银屑病病情严重程度的评价方法[J]. 诊断学理论与实践，2009，8(3): 360-362.
[26]刘海波，刘芳，桑红. 在皮肤学科指南中应用GRADE证据质量分级和推荐强度评价系统的意义[J]．中华皮肤科杂志，2018，51（9）: 639-641.

相似文献/References:

[1]张意,郭志丽,张勇.VitC和锌对游泳训练大鼠皮肤光老化的协同防护作用[J].医学研究与战创伤救治(原医学研究生学报),2016,18(04):337.[doi:10.3969/j.issn.1672-271X.2016.04.001]
　ZHANG Yi,GUO Zhi-li,ZHANG Yong..Synergistic effect of Vitamin C and Zn on anti-skin photoaging ability of swimming trainingrat[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(6):337.[doi:10.3969/j.issn.1672-271X.2016.04.001]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2021-12-15